Related Experiment Video
Updated: Jul 13, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Increased apoptosis induction by 121F mutant p53
1Swiss Institute for Experimental Cancer Research (ISREC), CH-1066 Epalinges, Switzerland.
Abstract:
p53 mutants in tumours have a reduced affinity for DNA and a reduced ability to induce apoptosis. We describe a mutant with the opposite phenotype, an increased affinity for some p53-binding sites and an increased ability to induce apoptosis. The apoptotic function requires transcription activation by p53. The mutant has an altered sequence specificity and selectively fails to activate MDM2 transcription. Loss of MDM2 feedback results in overexpression of the mutant, but the mutant kills better than wild-type p53 even in MDM2-null cells. Thus the apoptotic phenotype is due to a combination of decreased MDM2 feedback control and increased or unbalanced expression of other apoptosis-inducing p53 target genes. To identify these genes, DNA chips were screened using RNA from cells expressing the apoptosis-inducing mutant, 121F, and a sequence-specificity mutant with the reciprocal phenotype, 277R. Two potential new mediators of p53-dependent apoptosis were identified, Rad and PIR121, which are induced better by 121F than wild-type p53 and not induced by 277R. The 121F mutant kills untransformed MDM2-null but not wild-type mouse embryo fibroblasts and kills tumour cells irrespective of p53 status. It may thus expand the range of tumours which can be treated by p53 gene therapy.
Insights
A novel p53 mutant (121F) shows increased DNA binding and apoptosis induction, potentially expanding p53 gene therapy for tumors. This mutant selectively targets cancer cells by overcoming MDM2 feedback mechanisms.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Mutations in the p53 tumor suppressor gene are common in cancers, typically leading to reduced DNA binding and apoptosis induction.
- Understanding p53 mutant phenotypes is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To characterize a novel p53 mutant (121F) with enhanced apoptosis-inducing capabilities.
- To investigate the mechanisms underlying the increased apoptotic function and altered sequence specificity of the 121F mutant.
- To identify new p53 target genes involved in apoptosis.
Main Methods:
- Characterization of p53 mutant binding affinity and apoptosis induction.
- Analysis of MDM2 transcription activation and feedback regulation.
- DNA chip screening of RNA from cells expressing p53 mutants (121F and 277R).
Main Results:
- The 121F p53 mutant exhibits increased DNA binding affinity and apoptosis induction compared to wild-type p53.
- 121F selectively fails to activate MDM2 transcription, leading to its overexpression and enhanced apoptotic function.
- Two novel apoptosis mediators, Rad and PIR121, were identified as being better induced by 121F than wild-type p53.
- The 121F mutant demonstrates tumor cell killing irrespective of p53 status.
Conclusions:
- The 121F p53 mutant's potent apoptosis-inducing phenotype results from decreased MDM2 feedback and enhanced expression of specific target genes.
- The identification of Rad and PIR121 provides new insights into p53-mediated apoptosis pathways.
- The 121F mutant holds promise for expanding the scope of p53 gene therapy in various tumor types.
More Related Videos
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
Apoptosis
Caspases
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy

